When should a medical device company start building a go-to-market strategy?

Ideally before FDA clearance, so commercial planning runs in parallel with regulatory milestones. Companies that wait until after clearance to figure out the commercial side lose months of market positioning time while competitors establish themselves.

What are the most common go-to-market mistakes in medical devices?

Companies either move too slowly, paralyzed by complexity and watching competitors claim market position while they plan, or move too fast, scattering resources across too many targets and learning expensive lessons about healthcare purchasing the hard way. The key is sequencing activities logically so market relevance building and contract access run in parallel.

Does MedBridge help international companies entering the U.S. market?

Yes. International companies entering the U.S. healthcare market face unique challenges around GPO and IDN structures, distribution partnerships, reimbursement dynamics, and purchasing processes that differ significantly from other countries. We build strategies specifically designed for these market entry scenarios.

Market Intelligence & Go-to-Market Strategy

From Product to Market in a System That Wasn't Built for Speed

The U.S. healthcare market rewards preparation. We build the strategic roadmap that gets your product from clearance to contract to adoption.

The Challenge

Launching a medical device in the U.S. market means navigating GPO relationships, hospital procurement processes, value analysis committees, distributor partnerships, and competitive dynamics, all at once, all with different timelines.

Most companies make one of two mistakes. They move too slowly, paralyzed by complexity, trying to understand every variable before making a move, and watching competitors claim market position while they plan. Or they move too fast, scattering resources across too many targets, burning through sales budgets on unfocused efforts, and learning expensive lessons about healthcare purchasing the hard way.

The reality is that healthcare buying doesn't wait for you to figure it out, but it does punish companies that rush in without understanding the system. You need to be building market relevance, gaining share at a collection of hospitals, demonstrating clinical value, generating reference accounts, at the same time you're pursuing GPO contracts. These tracks have to run in parallel, and each has to inform the other.

Woman presents a global revenues chart to colleagues seated around a conference table

What We Bring

We build go-to-market strategies that sequence activities logically, allocate resources to their highest-value uses, and keep you focused on what matters most at each stage of market entry or expansion.

Market assessment sizing the opportunity, mapping the competitive landscape, and identifying the dynamics that will shape your entry
Segment prioritization determining which customer segments to pursue first, and equally important, which to defer
Positioning development defining how your product will be differentiated in the context of how healthcare actually evaluates and buys
Channel strategy determining the right mix of direct sales, distribution partnerships, and GPO/IDN access based on your product, resources, and market position
Launch sequencing with a phased roadmap including clear milestones and decision points
Resource planning defining the team, budget, and infrastructure needed to execute each phase

Man points to a launch timeline poster while three seated colleagues watch

What You Walk Away With

A market assessment with size, growth trajectory, and competitive analysis. A segment prioritization framework with clear targeting rationale. A positioning and messaging platform tailored to healthcare purchasing stakeholders. A channel strategy recommendation covering direct sales, distribution, and contract access. A phased launch roadmap with milestones, dependencies, and decision gates. And a resource plan with budget and headcount guidance for each phase.

Man in a navy blazer points at a printed chart while a colleague writes notes

Who This Is For

International companies entering the U.S. healthcare market

Startups launching their first commercial medical device product

Established companies expanding into new product categories or clinical areas

Companies that have FDA clearance but aren't sure how to navigate the commercial side

Dan Toomey shares insights on healthcare commercialization, market entry, and the realities of selling into U.S. hospitals in our Tuesday Talks with Toomey series, part of MedBridge's ongoing thought leadership platform.

Ready to Get Started?

Tell us where you are in your commercialization journey. We'll help you build a strategy that gets your product from clearance to contract to adoption.

Schedule a Meeting

Or call us directly: 443-277-2302